

June 23, 2022

**Alberta Securities Commission  
British Columbia Securities Commission  
Ontario Securities Commission**

Dear Sirs / Mesdames:

**Re: Gemina Laboratories Ltd. Prospectus Supplement dated June 23, 2022 to Short Form Base Shelf Prospectus dated January 10, 2022**

We refer to the prospectus supplement of the short form base shelf prospectus dated January 10, 2022 (the "Prospectus") of Gemina Laboratories Ltd. (the "Company") relating to the distribution of up to 8,334,000 units of the Company at a price of \$0.60 per unit for aggregate gross proceeds of up to \$5,000,400.


We consent to being named and to the use, through incorporation by reference in the above-mentioned Prospectus, of our report dated May 30, 2022 to the shareholders of the Company on the following consolidated financial statements:

Consolidated statements of financial position as at January 31, 2022 and 2021;

Consolidated statements of loss and comprehensive loss, changes in shareholders' equity and cash flows for the year ended January 31, 2022 and the period from incorporation on May 6, 2020 to January 31, 2021, and a summary of significant accounting policies and other explanatory information.

We report that we have read the Prospectus and all information therein and have no reason to believe that there are any misrepresentations in the information contained therein that are derived from the consolidated financial statements upon which we have reported or that are within our knowledge as a result of our audit of such consolidated financial statements. We have complied with Canadian generally accepted standards for an auditor's consent to the use of a report of the auditor included in an offering document, which does not constitute an audit or review of the Prospectus as these terms are described in the CPA Canada Handbook – Assurance.

Yours very truly,



**DAVIDSON & COMPANY LLP**  
Chartered Professional Accountants

